Arrowhead Pharmaceuticals, Inc. (ARWR)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 07, 2025

$19.67

P/E Ratio

N/A

Market Cap

$2.45B

Jan 22, 2024Feb 26, 2024Apr 1, 2024May 2, 2024Jun 5, 2024Jul 9, 2024Aug 8, 2024Sep 12, 2024Oct 17, 2024Nov 21, 2024Jan 7, 2025$30.00$40.00$50.00
  • APAM
Description

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Metrics

Overview

  • HQPasadena, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerARWR
  • Price$19.67+0.87%

Trading Information

  • Market cap$2.45B
  • Float93.24%
  • Average Daily Volume (1m)1,369,208
  • Average Daily Volume (3m)1,454,240
  • EPS-$5.00

Company

  • Revenue$3.55M
  • Rev growth (1yr)-98.52%
  • Net income-$599.49M
  • Gross margin-423.66%
  • EBITDA margin-16,403.41%
  • EBITDA-$582.49M
  • EV$2.50B
  • EV/Revenue703.12
  • P/EN/A
  • P/S663.52
  • P/B13.19
Documents